These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36806897)

  • 21. Gefitinib therapy for non-small cell lung cancer.
    Birnbaum A; Ready N
    Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhang S; Mao XD; Wang HT; Cai F; Xu J
    BMJ Open; 2016 Jun; 6(6):e011714. PubMed ID: 27363819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
    Liu GF; Li XF; Yu SN; Miao YY; Zhang SH
    J Cell Physiol; 2019 Apr; 234(4):3445-3457. PubMed ID: 30374969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
    Yamamoto N; Goto K; Nishio M; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Tajima K; Tamura T
    Int J Clin Oncol; 2017 Feb; 22(1):70-78. PubMed ID: 27659294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
    JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
    An N; Zhang Y; Niu H; Li Z; Cai J; Zhao Q; Li Q
    Medicine (Baltimore); 2016 Dec; 95(50):e5601. PubMed ID: 27977598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.
    Wu FZ; Song JJ; Zhao ZW; Huang XF; Mao JT; Tu JF; Chen MJ; Chen WQ; Fang SJ; Zheng LY; Fan XX
    Math Biosci Eng; 2019 Aug; 16(6):7921-7933. PubMed ID: 31698647
    [No Abstract]   [Full Text] [Related]  

  • 29. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
    Schuler M; Fischer JR; Grohé C; Gütz S; Thomas M; Kimmich M; Schneider CP; Laack E; Märten A;
    Oncologist; 2014 Oct; 19(10):1100-9. PubMed ID: 25232040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
    Fuster LM; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
    Reboul FL
    Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis.
    Créquit P; Chaimani A; Yavchitz A; Attiche N; Cadranel J; Trinquart L; Ravaud P
    BMC Med; 2017 Oct; 15(1):193. PubMed ID: 29082855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis.
    Ma H; Tian X; Zeng XT; Zhang Y; Wang Y; Wang F; Zhou JG
    Medicine (Baltimore); 2016 Jan; 95(2):e2495. PubMed ID: 26765461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
    PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
    Wu YL; Zhou C; Liam CK; Wu G; Liu X; Zhong Z; Lu S; Cheng Y; Han B; Chen L; Huang C; Qin S; Zhu Y; Pan H; Liang H; Li E; Jiang G; How SH; Fernando MCL; Zhang Y; Xia F; Zuo Y
    Ann Oncol; 2015 Sep; 26(9):1883-1889. PubMed ID: 26105600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with erlotinib in the treatment of non-small cell lung cancer.
    Landi L; Cappuzzo F
    Ther Adv Respir Dis; 2015 Aug; 9(4):146-63. PubMed ID: 26063687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
    Xu R; Shao H; Zhu J; Ju Q; Shi H
    Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
    Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B
    Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.